Accumulation of mutant p53(V143A) modulates the growth, clonogenicity, and radiochemosensitivity of malignant glioma cells independent of endogenous p53 status

Experimental Cell Research

Volumn 253, Issue 2, 1999, Pages 432-439

  Bartussek, Cornelia ^a   Naumann, Ulrike ^a   Weller, Michael ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Apoptosis; Chemotherapy; Glioma; p21(WAF1 CIP1); p53; Radiotherapy

Indexed keywords

CAMPTOTHECIN; CARMUSTINE; CISPLATIN; CYTOTOXIC AGENT; PACLITAXEL; PROTEIN P53; TENIPOSIDE; TOPOTECAN; VINCRISTINE;

ARTICLE; CANCER CELL; CELL DEATH; CELL GROWTH; CHEMOSENSITIVITY; CLONOGENESIS; CONTROLLED STUDY; GENE MUTATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RADIOSENSITIVITY;

EID: 0033572965     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1006/excr.1999.4654     Document Type: Article

References (42)

1. Blagosklonny M. V. Loss of function and p53 protein stabilization. Oncogene. 15:1997;1889-1893.
2. Chen P. L., Chen Y. M., Bookstein R., Lee W. H. Genetic mechanisms of tumor suppression by the human p53 gene. Science. 250:1990;1576-1580.
3. Shaulsky G., Goldfinger N., Rotter V. Alterations in tumor development in vivo mediated by expression of wild type or mutant p53 proteins. Cancer Res. 51:1991;5232-5237.
4. Dittmer D., Pati S., Zambetti G., Chu S., Teresky A. K., Moore M., Foster D., Anderson R. J., Levine A. J. Gain of function mutations in p53. Nat. Genet. 4:1993;42-46.
5. Trepel M., Scheding S., Groscurth P., Horny H. P., Malipiero U., Brugger W., Dichgans J., Weller M. A new look at the role of p53 in leukemia cell sensitivity to chemotherapy. Leukemia. 11:1997;1842-1849.
6. Gualberto A., Aldape K., Kozakiewicz K., Tlsty T. D. An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control. Proc. Natl. Acad. Sci. USA. 95:1998;5166-5171.
7. Lányi A., Deb D., Seymour R. C., Ludes-Meyers J. H., Subler M. A., Deb S. Gain of function phenotype of tumor-derived mutant p53 requires the oligomerization/nonsequence-specific nucleic acid-binding domain. Oncogene. 16:1998;3169-3176.
8. Li R., Sutphin P. D., Schwartz D., Matas D., Almog N., Wolkowicz R., Goldfinger N., Pei H., Prokocimer M., Rotter V. Mutant p53 protein expression interferes with p53-independent apoptotic pathways. Oncogene. 16:1998;3269-3277.
9. Trepel M., Groscurth P., Malipiero U., Gulbins E., Dichgans J., Weller M. Chemosensitivity of human malignant glioma: Modulation by p53 gene transfer. J. Neuro-Oncol. 39:1998;19-32.
10. Weller M. Predicting response to cancer chemotherapy: The role of p53. Cell Tissue Res. 292:1998;435-445.
11. Bögler O., Huang H. J. S., Kleihues P., Cavenee W. K. The p53 gene and its role in human brain tumors. Glia. 15:1995;308-327.
12. Fulci G., Ishii N., Van Meir E. G. p53 and brain tumors: From gene mutations to gene therapy. Brain Pathol. 8:1998;599-613.
13. Kleihues P., Schäuble B., zur Hausen A., Esteve J., Ohgaki H. Tumors associated with p53 germline mutations: A synopsis of 91 families. Am. J. Pathol. 150:1997;1-13.
14. Louis D. N., Gusella J. F. A tiger behind many doors: Multiple genetic pathways to malignant glioma. Trends Genet. 11:1995;412-415.
15. Watanabe K., Tachibana O., Sato K., Yonekawa Y., Kleihues P., Ohgaki H. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol. 6:1996;217-224.
16. Chozick B. S., Pezzullo J. C., Epstein M. H., Finch P. W. Prognostic implications of p53 overexpression in supratentorial astrocytic tumors. Neurosurgery. 35:1994;831-838.
17. Iwadate Y., Tagawa M., Fujimoto S., Hirose M., Namba H., Sueyoshi K., Sakiyama S., Yamaura A. Mutation of the p53 gene in human astrocytic tumors correlates with increased resistance to DNA-damaging agents but not to anti-microtubule anti-cancer agents. Br. J. Cancer. 77:1998;547-551.
18. Montine T. J., Bruner J. M., Vandersteenhoven J. J., Dodge R. K., Burger P. C. Prognostic significance of p53 immunoreactivity in adult patients with supratentorial fibrillary astrocytic neoplasms. Diagn. Mol. Pathol. 3:1994;240-245.
19. Kyritsis A. P., Bondy M. L., Hess K., Cunningham J. E., Zhu D., Amos C. J., Yung W. K. A., Levin V. A., Bruner J. M. Prognostic significance of p53 immunoreactivity in patients with glioma. Clin. Cancer Res. 1:1995;1617-1622.
20. Cunningham J. M., Kimmel D. W., Scheithauer B. W., O'Fallon J. R., Novotny P. J., Jenkins R. B. Analysis of proliferation markers and p53 expression in gliomas of astrocytic origin: Relationships and prognostic value. J. Neurosurg. 86:1997;121-130.
21. Ellison D. W., Steart P. V., Bateman A. C., Pickering R. M., Palmer J. D., Weller R. O. Prognostic indicators in a range of astrocytic tumors: An immunohistochemical study with Ki-67 and p53 antibodies. J. Neurol. Neurosurg. Psychiatry. 59:1995;413-419.
22. Soini Y., Niemelä A., Kamel D., Herva R., Bloigu R., Pääkkö P., Vähäkangas K. p53 immunohistochemical positivity as a prognostic marker in intracranial tumors. APMIS. 102:1994;786-792.
23. Pollack I. F., Hamilton R. L., Finkelstein S. D., Campbell J. W., Martinez A. J., Sherwin R. N., Bozik M. E., Gollin S. M. The relationship between TP53 mutations and overexpression of p53 and prognosis in malignant gliomas of childhood. Cancer Res. 57:1997;304-309.
24. Louis D. N., Von Deimling A., Chung R. Y., Rubio M. P., Whaley J. M., Eibl R. H., Ohgaki H., Wiestler O. D., Thor A. D., Seizinger B. R. Comparative study of p53 gene and protein alterations in human astrocytic tumors. J. Neuropathol. Exp. Neurol. 52:1993;31-38.
25. Newcomb E. W., Madonia W. J., Pisharody S., Lang F. F., Koslow M., Miller D. C. A correlative study of p53 protein alteration and p53 gene mutation in glioblastoma multiforme. Brain Pathol. 3:1993;229-235.
26. Reifenberger G., Liu L., Ichimura K., Schmidt E. E., Collins V. P. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res. 53:1993;2736-2739.
27. Rubio M. P., Von Deimling A., Yandell D. W., Wiestler O. D., Gusella J. F., Louis D. N. Accumulation of wild type p53 protein in human astrocytomas. Cancer Res. 53:1993;3465-3467.
28. Zhang W., Guo X. Y., Hu G. Y., Liu W. B., Shay J. W., Deisseroth A. B. A temperature-sensitive mutant of p53. EMBO J. 13:1994;2535-2544.
29. Friedlander P., Haupt Y., Prives C., Oren M. A mutant p53 that discriminates between p53-responsive genes cannot induce apoptosis. Mol. Cell. Biol. 16:1996;4961-4971.
30. McIlwrath A. J., Vasey P. A., Ross G. M., Brown R. Cell cycle arrests and radiosensitivity of human tumour cell lines: Dependence on wild-type p53 for radiosensitivity. Cancer Res. 54:1994;3718-3722.
31. Vasey P. A., Jones N. A., Jenkins S., Dive C., Brown R. Cisplatin, camptothecin, and Taxol sensitivities of cells with p53-associated drug resistance. Mol. Pharmacol. 50:1996;1536-1540.
32. McDonald A. C., Brown R. Induction of p53-dependent and independent cellular responses by topoisomerase 1 inhibitors. Br. J. Cancer. 78:1998;745-751.
33. Van Meir E. G., Kikuchi T., Tada M., Li H., Diserens A. C., Wojcik B. E., Huang H. J. S., Friedmann T., De Tribolet N., Cavenee W. K. Analysis of the p53 gene and its expression in human glioblastoma cells. Cancer Res. 54:1994;649-652.
34. Weller M., Rieger J., Grimmel C., Van Meir E. G., De Tribolet N., Krajewski S., Reed J. C., Von Deimling A., Dichgans J. Predicting chemoresistance in human malignant glioma cells: The role of molecular genetic analyses. Int. J. Cancer. 79:1998;640-644.
35. Baker S. J., Markowitz S., Fearon E. R., Willson J. K., Vogelstein B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science. 249:1990;912-915.
36. Appleman L. J., Frey A. B. Dominant-negative p53 can restore tumorigenicity of L-929 cells in immunocompetent mice. Int. J. Cancer. 63:1995;576-583.
37. his). Oncogene. 12:1996;715-725.
38. Graeber T. G., Osmanian C., Jacks T., Housman D. E., Koch C. J., Lowe S. W., Giacchia A. J. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors. Nature. 379:1996;88-91.
39. Harvey M., Vogel H., Morris D., Bradley A., Bernstein A., Donehower L. A. A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53-deficient mice. Nat. Genet. 9:1995;305-311.
40. Rauth S., Green A., Kichina J., Shilkaitis A. Suppression of tumorigenic and metastatic potentials of human melanoma cell lines by mutated (143 Val-Ala) p53. Br. J. Cancer. 77:1998;2215-2222.
41. Sidransky D., Mikkelsen T., Schwechheimer K., Rosenblum M. L., Cavenee W., Vogelstein B. Clonal expansion of p53 mutant cells is associated with brain tumor progression. Nature. 355:1992;846-847.
42. Haapasalo H., Isola J., Sallinen P., Kalimo H., Helin H., Rantala I. Aberrant p53 expression in astrocytic neoplasms of brain: Association with proliferation. Am. J. Pathol. 142:1993;1347-1351.